MorphoSys AG

General information
MorphoSys AG
Semmelweisstr. 7
82152 Planegg, Bavaria
Germany

Contact person: Jean-Paul Kress, Chief Executive Officer
Company main phone: +49 (89) 899270
Company main fax:  +49 (89) 89927222
Website:  https://www.morphosys.com
Year founded:1992
Source of foundation:Independent foundation
Name of foundation source:Founded by Dr. Simon Moroney and Prof. Dr. Andreas Pl├╝ckthun
No. of employees: Worldwide:  544
Corporate description / mission:
MorphoSys, is a global commercial-stage biopharmaceutical company, which discovers, develops, and delivers innovative cancer medicines to patients.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 1999
Remarks on ownership / listings
MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Antibodies
  • Immunotherapy
  • Small molecules
Primary therapeutic areas:
  • Cardiovascular / cardiology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • Musculoskeletal system and connective tissue / Orthopedics
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
Business model:
  • Manufacturer
  • Out-licensing
  • R&D
  • Supplier / Distributor
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
  • Small biotech
Distribution:
  • Direct (own sales force)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:2
Phase I:2
Phase II:7
Phase III:6
On the market:1
Description of products:
Tafasitamab
Pelabresib, etc.
Special IP situation:
MorphoSys has built a strong IP portfolio around its proprietary technology, HuCAL.
Technology used:
HuCAL (Human Combinatorial Antibody Library) technology
Financing details
Fiscal year (end of) 2022
Revenues:EUR 278.27M
R&D expenses:EUR 297.81M
No. of shares:34'170'100
Market cap. / valuation:EUR 974.19M
Collaborations & Clients
Partnering strategy / collaborations:
Novartis
I-Mab
GSK
pfizer
Ultragenyx and Mereo Biopharma etc
X